loading
Monte Rosa Therapeutics Inc stock is traded at $10.14, with a volume of 1.15M. It is up +1.20% in the last 24 hours and up +111.23% over the past month. Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$10.04
Open:
$10
24h Volume:
1.15M
Relative Volume:
1.00
Market Cap:
$626.24M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-4.5258
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
+32.64%
1M Performance:
+111.23%
6M Performance:
+140.76%
1Y Performance:
+106.09%
1-Day Range:
Value
$9.5407
$10.32
1-Week Range:
Value
$7.235
$10.32
52-Week Range:
Value
$3.5001
$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name
Name
Monte Rosa Therapeutics Inc
Name
Phone
617-949-2643
Name
Address
321 HARRISON AVENUE, BOSTON
Name
Employee
142
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
GLUE's Discussions on Twitter

Compare GLUE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GLUE
Monte Rosa Therapeutics Inc
10.14 620.06M 0 -130.41M -67.76M -2.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.56 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.33 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.46 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
800.99 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
330.86 35.16B 4.56B -176.77M 225.30M -1.7177

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-19-24 Downgrade Wells Fargo Overweight → Equal Weight
Feb-15-24 Initiated Wedbush Outperform
Jan-03-23 Upgrade Wells Fargo Equal Weight → Overweight
Oct-13-22 Initiated UBS Buy
Aug-15-22 Initiated Jefferies Buy
Apr-28-22 Initiated Credit Suisse Neutral
Feb-10-22 Initiated Wells Fargo Equal Weight
Oct-14-21 Initiated SVB Leerink Mkt Perform
View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

pulisher
11:29 AM

Using data models to predict Monte Rosa Therapeutics Inc. stock movementEarnings Beat & High Accuracy Buy Signal Tips - newser.com

11:29 AM
pulisher
11:11 AM

Applying sector rotation models to Monte Rosa Therapeutics Inc.Profit Target & Step-by-Step Trade Execution Guides - newser.com

11:11 AM
pulisher
10:34 AM

Using economic indicators to assess Monte Rosa Therapeutics Inc. potentialTreasury Yields & AI Powered Market Entry Strategies - newser.com

10:34 AM
pulisher
09:44 AM

Why Monte Rosa Therapeutics Inc. stock could benefit from AI revolutionMarket Activity Summary & Technical Pattern Based Buy Signals - newser.com

09:44 AM
pulisher
Oct 11, 2025

Monte Rosa Therapeutics (NASDAQ:GLUE) Sees Unusually-High Trading VolumeHere's Why - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 7.9%Here's Why - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Monte Rosa Therapeutics Inc. stock momentum explainedWeekly Gains Summary & Verified Entry Point Signals - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

What analysts say about Monte Rosa Therapeutics Inc stockValue Traps to Avoid & Outstanding Growth Strategies - earlytimes.in

Oct 10, 2025
pulisher
Oct 10, 2025

Does Monte Rosa Therapeutics Inc. fit your quant trading modelJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Monte Rosa Therapeutics Forms Golden Cross, Signals Bullish Breakout Ahead - Markets Mojo

Oct 09, 2025
pulisher
Oct 09, 2025

Signal strength of Monte Rosa Therapeutics Inc. stock in tech scannersDollar Strength & Low Drawdown Momentum Trade Ideas - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Monte Rosa Therapeutics (NASDAQ:GLUE) Earns "Sell (D)" Rating from Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 06, 2025

Will Monte Rosa Therapeutics Inc. see short term momentum2025 AllTime Highs & Low Drawdown Investment Ideas - newser.com

Oct 06, 2025
pulisher
Oct 03, 2025

Comparing Monte Rosa Therapeutics Inc. in custom built stock radarsJuly 2025 Analyst Calls & Real-Time Volume Spike Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

How high can Monte Rosa Therapeutics Inc. stock goShort Setup & Advanced Technical Analysis Signals - newser.com

Oct 03, 2025
pulisher
Sep 30, 2025

Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects - Insider Monkey

Sep 30, 2025
pulisher
Sep 29, 2025

11 Best Fast Money Stocks to Buy Now - Insider Monkey

Sep 29, 2025
pulisher
Sep 29, 2025

Is Monte Rosa Therapeutics Inc a good long term investmentGeopolitical Risk Analysis & Consistent Double Returns - earlytimes.in

Sep 29, 2025
pulisher
Sep 28, 2025

Monte Rosa Therapeutics Inc Stock Analysis and ForecastLarge Cap Stability Picks & Fast Profit Trading Ideas - earlytimes.in

Sep 28, 2025
pulisher
Sep 27, 2025

Full technical analysis of Monte Rosa Therapeutics Inc. stockBuy Signal & Accurate Buy Signal Notifications - newser.com

Sep 27, 2025
pulisher
Sep 26, 2025

Is Monte Rosa Therapeutics Inc. stock reversal real or fakeWatch List & Daily Chart Pattern Signals - newser.com

Sep 26, 2025
pulisher
Sep 24, 2025

Monte Rosa Therapeutics Inc. stock trend forecastJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com

Sep 24, 2025
pulisher
Sep 24, 2025

Pallas Capital Advisors LLC Makes New $59,000 Investment in Monte Rosa Therapeutics, Inc. $GLUE - Defense World

Sep 24, 2025
pulisher
Sep 23, 2025

Monte Rosa Therapeutics presents new CDK2 degradation inducers - BioWorld MedTech

Sep 23, 2025
pulisher
Sep 23, 2025

Monte Rosa Is Building The ‘Next RNAi’ Through AI-Powered Molecular Glue Discovery - insights.citeline.com

Sep 23, 2025
pulisher
Sep 22, 2025

Will Monte Rosa Therapeutics Inc. stock go up soonJuly 2025 Fed Impact & Community Consensus Picks - newser.com

Sep 22, 2025
pulisher
Sep 22, 2025

Sentiment analysis tools applied to Monte Rosa Therapeutics Inc.July 2025 Big Picture & Stepwise Entry and Exit Trade Signals - newser.com

Sep 22, 2025
pulisher
Sep 21, 2025

Q3 EPS Forecast for Monte Rosa Therapeutics Cut by Analyst - MarketBeat

Sep 21, 2025
pulisher
Sep 21, 2025

Aug EndMonth: Can Monte Rosa Therapeutics Inc disrupt its industryPortfolio Value Summary & Free High Accuracy Swing Entry Alerts - خودرو بانک

Sep 21, 2025
pulisher
Sep 20, 2025

Market Moves: Can Monte Rosa Therapeutics Inc. disrupt its industry2025 Retail Activity & Growth Oriented Trading Recommendations - خودرو بانک

Sep 20, 2025

Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Monte Rosa Therapeutics Inc Stock (GLUE) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Leo Chandra P.
Director
Mar 24 '25
Buy
5.84
10,000
58,383
10,000
Versant Venture Capital VI, L.
10% Owner
Oct 28 '24
Sale
9.66
89,990
869,240
2,007,948
Versant Venture Capital VI, L.
10% Owner
Oct 29 '24
Sale
9.16
67,905
621,801
1,573,453
$85.13
price up icon 1.59%
$22.83
price up icon 7.21%
$32.80
price up icon 3.03%
$102.59
price up icon 0.56%
$165.04
price up icon 1.60%
biotechnology ONC
$330.86
price up icon 3.39%
Cap:     |  Volume (24h):